List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2702368/publications.pdf Version: 2024-02-01



Ρλοιλ Ελοολ

#	Article	IF	CITATIONS
1	Sex differences in addictive disorders. Frontiers in Neuroendocrinology, 2014, 35, 272-284.	2.5	211
2	Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse, 2003, 50, 1-6.	0.6	184
3	Cannabinoid selfâ€∎dministration in rats: sex differences and the influence of ovarian function. British Journal of Pharmacology, 2007, 152, 795-804.	2.7	172
4	Sleep deprivation in the rat: an animal model of mania. European Neuropsychopharmacology, 1995, 5, 89-93.	0.3	156
5	Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 482-490.	1.3	132
6	Synthetic and plantâ€derived cannabinoid receptor antagonists show hypophagic properties in fasted and nonâ€fasted mice. British Journal of Pharmacology, 2009, 156, 1154-1166.	2.7	120
7	Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. Biological Psychiatry, 2011, 69, 633-641.	0.7	112
8	Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing to Drug Addiction: Effect of Ovarian Hormones. Current Pharmaceutical Design, 2014, 20, 2100-2113.	0.9	108
9	Cannabinoid self-administration increases dopamine release in the nucleus accumbens. NeuroReport, 2006, 17, 1629-1632.	0.6	101
10	Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology, 2004, 47, 1170-1179.	2.0	98
11	Endocannabinoid system and opioid addiction: Behavioural aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 343-359.	1.3	97
12	Cannabinoids and Reward: Interactions with the Opioid System. Critical Reviews in Neurobiology, 2004, 16, 147-158.	3.3	95
13	Drug―and cue―nduced reinstatement of cannabinoidâ€seeking behaviour in male and female rats: influence of ovarian hormones. British Journal of Pharmacology, 2010, 160, 724-735.	2.7	94
14	An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives. Brain Research Reviews, 2007, 53, 1-16.	9.1	90
15	Involvement of κ-Opioid and Endocannabinoid System on Salvinorin A-Induced Reward. Biological Psychiatry, 2008, 63, 286-292.	0.7	89
16	CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. British Journal of Pharmacology, 2004, 143, 343-350.	2.7	84
17	Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology, 2005, 48, 1097-1104.	2.0	82
18	PPARα Regulates Cholinergic-Driven Activity of Midbrain Dopamine Neurons via a Novel Mechanism Involving α7 Nicotinic Acetylcholine Receptors. Journal of Neuroscience, 2013, 33, 6203-6211.	1.7	79

#	Article	IF	CITATIONS
19	The endocannabinoid system and nondrug rewarding behaviours. Experimental Neurology, 2010, 224, 23-36.	2.0	78
20	Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. European Journal of Neuroscience, 2007, 25, 2191-2200.	1.2	74
21	Sex differences in the self-administration of cannabinoids and other drugs of abuse. Psychoneuroendocrinology, 2009, 34, S227-S236.	1.3	71
22	STRESS-INDUCED SLEEP DEPRIVATION MODIFIES CORTICOTROPIN RELEASING FACTOR (CRF) LEVELS AND CRF BINDING IN RAT BRAIN AND PITUITARY. Pharmacological Research, 1997, 35, 443-446.	3.1	67
23	Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology, 2007, 52, 646-654.	2.0	67
24	Neurobiological mechanisms of cannabinoid addiction. Molecular and Cellular Endocrinology, 2008, 286, S97-S107.	1.6	66
25	Sleep deprivation increases dopamine D1 receptor antagonist [3H]SCH 23390 binding and dopamine-stimulated adenylate cyclase in the rat limbic system. Neuroscience Letters, 1990, 117, 224-227.	1.0	65
26	Chronic morphine and naltrexone fail to modify μ-opioid receptor mRNA levels in the rat brain. Molecular Brain Research, 1997, 45, 149-153.	2.5	64
27	Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice. Synapse, 2005, 56, 29-38.	0.6	63
28	The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology, 2007, 52, 1555-1562.	2.0	60
29	Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. International Journal of Molecular Sciences, 2021, 22, 1863.	1.8	60
30	Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. European Neuropsychopharmacology, 2009, 19, 487-498.	0.3	58
31	Maternal Immune Activation Disrupts Dopamine System in the Offspring. International Journal of Neuropsychopharmacology, 2016, 19, pyw007.	1.0	58
32	The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotineâ€induced dopamine elevations in the nucleus accumbens shell in rats. British Journal of Pharmacology, 2012, 165, 2539-2548.	2.7	56
33	Sleep deprivation decreases μ and δopioid receptor binding in the rat limbic system. Neuroscience Letters, 1991, 129, 315-317.	1.0	54
34	Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. European Neuropsychopharmacology, 2010, 20, 25-36.	0.3	54
35	Adolescent Δ9-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats. Neuropsychopharmacology, 2016, 41, 1416-1426.	2.8	53
36	Brain activity of anandamide: a rewarding bliss?. Acta Pharmacologica Sinica, 2019, 40, 309-323.	2.8	53

#	Article	IF	CITATIONS
37	Differences in the Opioid System in Selected Brain Regions of Alcohol-Preferring and Alcohol-Nonpreferring Rats. Alcoholism: Clinical and Experimental Research, 1999, 23, 1296-1305.	1.4	48
38	Endocannabinoid regulation of relapse mechanisms. Pharmacological Research, 2007, 56, 418-427.	3.1	47
39	Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology, 2016, 233, 1765-1777.	1.5	39
40	Cannabinoid exposure in rat adolescence reprograms the initial behavioral, molecular, and epigenetic response to cocaine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9991-10002.	3.3	39
41	Cannabinoid CB ₁ /CB ₂ receptor agonists attenuate hyperactivity and body weight loss in a rat model of activityâ€based anorexia. British Journal of Pharmacology, 2017, 174, 2682-2695.	2.7	33
42	Dopamine and opioids interactions in sleep deprivation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1993, 17, 269-278.	2.5	32
43	The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction. CNS and Neurological Disorders - Drug Targets, 2008, 7, 468-481.	0.8	32
44	Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Frontiers in Pharmacology, 2014, 5, 44.	1.6	32
45	Cannabinoid-Opioid Interactions in Drug Discrimination and Self-Administration: Effect of Maternal, Postnatal, Adolescent and Adult Exposure to the Drugs. Current Drug Targets, 2010, 11, 450-461.	1.0	31
46	Pharmacological modulation of the endocannabinoid signalling alters bingeâ€ŧype eating behaviour in female rats. British Journal of Pharmacology, 2013, 169, 820-833.	2.7	31
47	New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. Medicines (Basel,) Tj ETQq	1 1 0,7843 0.7	14 rgBT /Ove
48	The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence. Current Pharmaceutical Design, 2014, 20, 2089-2099.	0.9	30
49	Dopamine D1 and opioid receptor binding changes in the limbic system of sleep deprived rats. Neurochemistry International, 1992, 20, 153-156.	1.9	28
50	Scopolamine and MK801-induced working memory deficits in rats are not reversed by CBD-rich cannabis extracts. Behavioural Brain Research, 2006, 168, 307-311.	1.2	28
51	Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behavioural Pharmacology, 2016, 27, 489-496.	0.8	26
52	Inhibition of N-acylethanolamine acid amidase reduces nicotine-induced dopamine activation and reward. Neuropharmacology, 2019, 144, 327-336.	2.0	24
53	Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8535.	1.8	24
54	Cannabinoid Modulation of Eukaryotic Initiation Factors (eIF2α and eIF2B1) and Behavioral Cross-Sensitization to Cocaine in Adolescent Rats. Cell Reports, 2018, 22, 2909-2923.	2.9	23

#	Article	IF	CITATIONS
55	Adolescent cannabinoid exposure induces irritability-like behavior and cocaine cross-sensitization without affecting the escalation of cocaine self-administration in adulthood. Scientific Reports, 2018, 8, 13893.	1.6	23
56	The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission. Psychopharmacology, 2016, 233, 2241-2251.	1.5	22
57	Δ9-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation. Frontiers in Behavioral Neuroscience, 2019, 13, 202.	1.0	22
58	Δ9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity. PLoS ONE, 2014, 9, e98079.	1.1	22
59	Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcoholism: Clinical and Experimental Research, 1999, 23, 1296-305.	1.4	22
60	Chronic imipramine, l-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. Neuroscience Letters, 1995, 192, 121-123.	1.0	21
61	Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology, 2013, 225, 531-542.	1.5	21
62	Methoxetamine affects brain processing involved in emotional response in rats. British Journal of Pharmacology, 2017, 174, 3333-3345.	2.7	21
63	Reduction of Corticostriatal Glutamatergic Fibers in Basic Fibroblast Growth Factor Deficient Mice is Associated with Hyperactivity and Enhanced Dopaminergic Transmission. Biological Psychiatry, 2007, 62, 235-242.	0.7	20
64	Differential effect of opioid and cannabinoid receptor blockade on heroinâ€seeking reinstatement and cannabinoid substitution in heroinâ€abstinent rats. British Journal of Pharmacology, 2011, 163, 1550-1562.	2.7	20
65	Limited Access to a High Fat Diet Alters Endocannabinoid Tone in Female Rats. Frontiers in Neuroscience, 2018, 12, 40.	1.4	19
66	Impaired brain endocannabinoid tone in the activityâ€based model of anorexia nervosa. International Journal of Eating Disorders, 2019, 52, 1251-1262.	2.1	19
67	Synthesis, Molecular Modeling, and Opioid Receptor Affinity of 9,10-Diazatricyclo[4.2.1.12,5]decanes and 2,7-Diazatricyclo[4.4.0.03,8]decanes Structurally Related to 3,8-Diazabicyclo[3.2.1]octanes. Journal of Medicinal Chemistry, 2000, 43, 2115-2123.	2.9	15
68	Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptorâ€f1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl) pyrrolo[1,2,3-de]-1,4-benzoxazin European Journal of Neuroscience, 2007, 25, 3305-3311.	1.2	15
69	Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat. Psychopharmacology, 2015, 232, 91-100.	1.5	15
70	N-3(9)-Arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-Opioid receptor agonists. Effects on μ-Affinity of arylalkenyl chain modifications. Bioorganic and Medicinal Chemistry, 2002, 10, 1929-1937.	1.4	14
71	Cannabinoids and their therapeutic applications in mental disorders. Dialogues in Clinical Neuroscience, 2020, 22, 271-279.	1.8	13
72	Chronic blockade of CB ₁ receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. British Journal of Pharmacology, 2012, 167, 1652-1664.	2.7	12

#	Article	IF	CITATIONS
73	Emotional profile of female rats showing binge eating behavior. Physiology and Behavior, 2016, 163, 136-143.	1.0	12
74	The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB1 receptor density and function. Pharmacological Research, 2017, 115, 209-217.	3.1	12
75	Epigenetic regulation of the cannabinoid receptor <scp>CB1</scp> in an activityâ€based rat model of anorexia nervosa. International Journal of Eating Disorders, 2020, 53, 702-716.	2.1	12
76	Repeated exposure to JWHâ€018 induces adaptive changes in the mesolimbic and mesocortical dopaminergic pathways, glial cells alterations, and behavioural correlates. British Journal of Pharmacology, 2021, 178, 3476-3497.	2.7	12
77	Synthesis and μ-opioid receptor affinity of a new series of nitro substituted 3,8-diazabicyclo[3.2.1]octane derivatives. Il Farmaco, 1998, 53, 557-562.	0.9	9
78	Presenting Psychiatric and Neurological Symptoms and Signs of Brain Tumors before Diagnosis: A Systematic Review. Brain Sciences, 2021, 11, 301.	1.1	9
79	Antinociceptive action of DBO 17 and DBO 11 in mice: two 3,8 diazabicyclo (3.2.1.) octane derivates with selective μ opioid receptor affinity. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 596-602.	1.4	8
80	Sex-specific differences in cannabinoid-induced extracellular-signal-regulated kinase phosphorylation in the cingulate cortex, prefrontal cortex, and nucleus accumbens of Lister Hooded rats. Behavioural Pharmacology, 2018, 29, 473-481.	0.8	8
81	Animal Models of Eating Disorders. Methods in Molecular Biology, 2019, 2011, 297-314.	0.4	8
82	Altered brain levels of arachidonic acid-derived inflammatory eicosanoids in a rodent model of anorexia nervosa. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158578.	1.2	8
83	Role of Opioid Receptors in the Reinstatement of Opioid-Seeking Behavior: An Overview. Methods in Molecular Biology, 2015, 1230, 281-293.	0.4	6
84	C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures. , 1996, 24, 297-304.		5
85	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ Open, 2017, 7, e014938.	0.8	5
86	Conditioned Place Preference (CPP) in Rats: From Conditioning to Reinstatement Test. Methods in Molecular Biology, 2021, 2201, 221-229.	0.4	5
87	Benzocondensed derivatives as rigid analogues of the μ-opioid agonist 3(8)-cinnamyl-8(3)-propionyl-3,8-diazabicyclo[3.2.1]octanes: synthesis, modeling, and affinity. Il Farmaco, 1998, 53, 667-674.	0.9	4
88	Monocyclic analogues of the μ-opioid agonist 3,8-diazabicyclo [3.2.1]octanes: Synthesis, modeling, and activity. Tetrahedron, 1995, 51, 11547-11556.	1.0	3
89	Analysis of Opioid-Seeking Behavior Through the Intravenous Self-Administration Reinstatement Model in Rats. Methods in Molecular Biology, 2021, 2201, 231-245.	0.4	3
90	Dopamine receptor gene expression in rat lines selected for ethanol preference or aversion. Behavioural Pharmacology, 1995, 6, 8.	0.8	2

#	Article	IF	CITATIONS
91	Synthesis and κ binding affinity of 1-(pyrrolidin-1-ylmethyl)-2-(N-methyl)-4-[(3,4-dichloro)phenyl]-1,2,3,4 tetrahydroisoquinolin-3(2H)-ones. European Journal of Medicinal Chemistry, 1995, 30, 515-520.	2.6	2
92	The endocannabinoid system. , 2015, , 389-413.		2
93	Anxiety profile and pituitary CRF contents of alcohol-preferring sP and non-preferring sNP rats. Behavioural Pharmacology, 1995, 6, 7.	0.8	1
94	Analysis of Opioid-Seeking Reinstatement in the Rat. Methods in Molecular Biology, 2015, 1230, 295-307.	0.4	1
95	Possible role of corticotropin-releasing factor (CRF) in an animal model of stress and depression. Pharmacological Research, 1992, 26, 254.	3.1	о
96	RT-PCR. Behavioural Pharmacology, 1995, 6, 121.	0.8	0
97	P24 DRUG-INDUCED REINSTATEMENT OF EXTINGUISHED CANNABINOID-SEEKING BEHAVIOUR IN RATS. Behavioural Pharmacology, 2004, 15, A15.	0.8	О
98	P.049 The impact of depot and long acting injectable antipsychotics on BDNF serum levels in psychosis: a 24-month longitudinal prospective study. European Neuropsychopharmacology, 2019, 29, 554-555	0.3	0

a 24-month longitudinal prospective study. European Neuropsychopharmacology, 2019, 29, \$54-S55.